High efficiency capture of biomarker miRNA15a for noninvasive diagnosis of malignant kidney tumors

Renner, Alexander M.; Derichsweiler, Christina; Ilyas, Shaista; Gessner, Isabel; Fries, Jochen W.U.; Mathur, Sanjay

doi:10.1039/d1bm01737c

Cited by 11 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The particles were extracted from urine and purified by magnetic separation to remove all cell debris and potential disruptive factors. After fluorescence labeling by the second ss-oligonucleotides, the amount of miRNA15a can be quantified based on its emission signal in an ELISA reader [ 53 ]; D. Schematic diagram illustrating the capture mechanism using dendrimer-mediated multivalent binding effect, cell rolling, and RCC-specific antibody cocktail [ 59 ]. …”

Section: Materials Used For Early Diagnosis Of Rccmentioning

confidence: 99%

“…For example, MiRNA15a, known for its high specificity and sensitivity in detecting RCC, has demonstrated reliability as a biomarker [ 52 ]. The predictive value of the biotin-streptavidin-binding and fluorescence-activated magnetic nanocarrier method for isolating miRNA15a from RCC patient urine has been demonstrated by Mathur et al This method offers a cost-effective and rapid alternative to real-time quantitative polymerase chain reaction assays, potentially improving patient compliance and enabling non-invasive investigation and early detection of RCC [ 53 ]. ( Fig.…”

Section: Materials Used For Early Diagnosis Of Rccmentioning

confidence: 99%

See 1 more Smart Citation

Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials

Li,

Luo,

Liu

et al. 2024

Materials Today Bio

View full text Add to dashboard Cite

Section: Materials Used For Early Diagnosis Of Rccmentioning

confidence: 99%

Section: Materials Used For Early Diagnosis Of Rccmentioning

confidence: 99%

Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials

Li,

Luo,

Liu

et al. 2024

Materials Today Bio

View full text Add to dashboard Cite

“…Nanocarriers are nanomaterials with particle size typically less than 500 nm in diameter and are frequently used as transport vehicles for other substances [ 53 ]. Alexander M Renner et al reported a non-invasive quantitative approach through biotin-streptavidin binding and fluorescence active magnetic nanocarriers that ensured prompt isolation, enrichment and purification of the biomarker miRNA15a from urine [ 54 ]. This approach involved the chemically engineered magnetic nanocarriers equipped with surface-attached ss-oligonucleotides, which can be used to separate tumor-related miRNA15a within a few hours.…”

Section: Diagnosis Of Renal Cell Carcinoma Using Nanomedicinementioning

confidence: 99%

“…The detection of miRNA-204 and miRNA-210 related to the RCC [17] Biotin-streptavidin binding and fluorescence active magnetic nanocarriers Human study Detectable low levels of miRNA15a through miRNA capturing nanocarriers [54] EVs detected by nanoparticle tracking analysis…”

Section: In Vitromentioning

confidence: 99%

Nanomedicine for renal cell carcinoma: imaging, treatment and beyond

Wang

Gai

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

The kidney is a vital organ responsible for maintaining homeostasis in the human body. However, renal cell carcinoma (RCC) is a common malignancy of the urinary system and represents a serious threat to human health. Although the overall survival of RCC has improved substantially with the development of cancer diagnosis and management, there are various reasons for treatment failure. Firstly, without any readily available biomarkers, timely diagnosis has been greatly hampered. Secondly, the imaging appearance also varies greatly, and its early detection often remains difficult. Thirdly, chemotherapy has been validated as unavailable for treating renal cancer in the clinic due to its intrinsic drug resistance. Concomitant with the progress of nanotechnological methods in pharmaceuticals, the management of kidney cancer has undergone a transformation in the recent decade. Nanotechnology has shown many advantages over widely used traditional methods, leading to broad biomedical applications ranging from drug delivery, prevention, diagnosis to treatment. This review focuses on nanotechnologies in RCC management and further discusses their biomedical translation with the aim of identifying the most promising nanomedicines for clinical needs. As our understanding of nanotechnologies continues to grow, more opportunities to improve the management of renal cancer are expected to emerge.

show abstract

“…Regardless of the nature of the therapeutic agents (e.g., small molecules, RNA/DNA, or macromolecular bioconjugates) or the carriers (e.g., organic liposomes or inorganic nanoparticles), drug–carrier conjugates can reach the target site/cell via “passive” or “active” uptake mechanisms. − The efficiency of active drug uptake depends on the diffusion of the drug–carrier complex through the membrane to release the drug in the microenvironment of the tumor . For a long time, the carrier-facilitated drug uptake was considered to be affected by an enhanced permeation and retention (EPR) effect intrinsic to the leaky tumor vasculature.…”

Section: Introductionmentioning

confidence: 99%

Validation of Dual-Action Chemo-Radio-Labeled Nanocarriers with High Efficacy against Triple-Negative Breast Cancer

Ilyas,

E. M. Sahnoun,

Szymura

et al. 2023

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

Identification and selectivity of molecular targets with prolonged action for difficult-to-target cancer such as triple-negative breast cancer (TNBC) represent a persisting challenge in the precision delivery of therapeutics. In the quest to target undruggable sites, this study validates the bioavailability of polydopamine-sealed mesoporous silica nanocarriers (PDA-mSiO 2 ) for in vivo drug delivery to TNBC. For controlled transport and release, the chemotherapeutic drug doxorubicin was encapsulated in mSiO 2 nanocarriers coated with a PDA layer serving as a stimuli-responsive gatekeeper or seal. For unifying targeting and treatment modalities, these nanocarriers were covalently conjugated to a macrocyclic chelator (DOTA) and folate (FA-mSiO 2. ) that enabled incorporation of radionuclides and identification of FR Alpha (FolRα) receptors present on TNBC cells. The robust chemical design of FA-and DOTA-functionalized PDA-coated mSiO 2 nanocarriers constitutes mild reaction conditions to avoid the loss of surface-bound molecules. The radiolabeling studies with the theranostic pair 68 Ga and 177 Lu showed quantitative trends for radiochemical efficacy and purity. Nanocarriers equipped with both radiolabels and affinity ligands were optimally stable when incubated with human serum for up to 120 h ( 177 Lu), demonstrating hydrophilicity with a partition coefficient (log P) of −3.29 ± 0.08. Specifically, when incubated with TNBC cells, the cells received significant FA-mSiO 2 carriers, demonstrating efficient carrier internalization and time-dependent uptake. Moreover, in vivo results visualize the retention of drug-filled carriers at the tumor sites for a long time, which holds promise for therapeutic studies. This research work demonstrates for the first time the successful dual conjugation of nanocarriers through the colocation of radionuclides and anticancer drugs that is promising for both live molecular imaging and enhanced therapeutic effect for TNBC.

show abstract

High efficiency capture of biomarker miRNA15a for noninvasive diagnosis of malignant kidney tumors

Abstract: A non-invasive diagnostic tool for RCC via magnetic carriers, utilizing miRNA15a as a biomarker offers several advantages over the “gold standard” of qRT-PCR in terms of: handling, equipment needed, duration, ease of test manufacturing and costs.

Cited by 11 publications

References 44 publications

Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials

Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials

Nanomedicine for renal cell carcinoma: imaging, treatment and beyond

Validation of Dual-Action Chemo-Radio-Labeled Nanocarriers with High Efficacy against Triple-Negative Breast Cancer

Contact Info

Product

Resources

About